Last reviewed · How we verify

NCT07093320: SARCOVASCPLAST

Saving Limbs After Cancer: Blood Vessel and Soft Tissue Reconstruction Following Sarcoma Surgery in the Legs

Completed Last updated 30 July 2025
What this trial tests

trial testing No intervention in Soft Tissue Sarcoma (STS) in 16 participants. Completed in 31 December 2024.

Timeline
1 December 2019
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorEuropean Georges Pompidou Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment16
Start date1 December 2019
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

European Georges Pompidou Hospital

Who can join

Eligibility, any sex, with Soft Tissue Sarcoma (STS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate whether immediate reconstruction of blood vessels and soft tissues can safely and effectively preserve limbs in patients undergoing surgery for sarcomas involving major arteries or veins in the arms or legs. The goal was to determine if this complex surgical approach helps avoid amputation, ensures good cancer control, and leads to acceptable complication rates and healing outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Soft Tissue Sarcoma (STS)

Currently open trials in the same condition.

Other European Georges Pompidou Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07093320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing